Evaluation of the diagnostic performance of estimated fecal calprotectin and serum intelectin-1 and C-reactive protein solo or in combination for differentiation between patients with query ulcerative colitis, Crohn’s disease and irritable bowel syndrome

Naima Fellak

doi:10.53730/ijhs.v8nS1.14756

Authors

Naima Fellak Specialist Internal Medicine, United Arab Emirates

Keywords:

fecal calprotectin, intelectin-1, C-reactive protein, ulcerative colitis, irritable bowel syndrome

Abstract

Background: Gut-brain contact has been linked recently to functional gastrointestinal problems. This interaction begins with immune cells invading the mucosa, which then causes intestinal cells to release nociceptive mediators either directly or indirectly. These mediators can cause visceral hypersensitivity by activating sensitized neurons. Reduced serum levels of intelectin-1 may distinguish among studied cases with UC & healthy controls as well as among IBS studied cases & studied cases with UC. This is as UC studied case samples had significantly lower levels of ITLN1 than do control & IBS studied case samples, & IBS studied case samples & healthy controls did not differ significantly. Aim: in this review; Our objective was to assess the diagnostic efficacy of serum intelectin-1, C-reactive protein, & estimated faecal calprotectin alone or in combination for distinguishing individuals with ulcerative colitis from those with irritable bowel syndrome, Summary: High FCP & low serum ITLN1 together can be able to distinguish UC from IBS, predict colonoscopic & microscopic results of UC, & avoid the need for colonoscopy & biopsy, particularly in IBS studied cases. Raised FCP & lowered serum ITLN1 may distinguish UC from IBS by precisely predicting the microscopic & colonoscopic diagnostic results of UC.

Downloads

Download data is not yet available.

References

Thunberg, J., Björkqvist, O., Hedin, C. R. H., Forss, A., Söderman, C., Bergemalm, D., et al. (2022). Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register. United European Gastroenterology Journal, 10(7), 631–639.

Dajti, E., Frazzoni, L., Iascone, V., Secco, M., Vestito, A., Fuccio, L., et al. (2023). Systematic review with meta‐analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults. Alimentary Pharmacology & Therapeutics.

Lee, Y. W., Lee, K.-M., Lee, J. M., Chung, Y. Y., Kim, D. B., Kim, Y. J., et al. (2019). The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity. The Korean Journal of Internal Medicine, 34(1), 72.

Fabian, O., Bajer, L., Drastich, P., Harant, K., Sticova, E., Daskova, N., et al. (2023). A Current State of Proteomics in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Search and Review. International Journal of Molecular Sciences, 24(11), 9386.

Campbell, J. P., Zierold, C., Rode, A. M., Blocki, F. A., Vaughn, B. P. (2021). Clinical performance of a novel LIAISON fecal calprotectin assay for differentiation of inflammatory bowel disease from irritable bowel syndrome. Journal of Clinical Gastroenterology, 55(3), 239.

Sarhan, R. S. R., Marei, Y. M., Marei, Y. M. (2023). Evaluation of the diagnostic performance of estimated fecal calprotectin and serum intelectin-1 and C-reactive protein solo or in combination for differentiation between patients with query ulcerative colitis and irritable bowel syndrome. The Egyptian Journal of Internal Medicine, 35(1), 79.

Grgić, D., Golubić, K., Brinar, M., Krznarić, Ž. (2022). Predictive value of faecal calprotectin in ulcerative colitis–single centre experience. Annals of Medicine, 54(1), 1570–1577.

Dulai, P. S., Battat, R., Barsky, M., Nguyen, N. H., Ma, C., Narula, N., et al. (2020). Incorporating fecal calprotectin into clinical practice for patients with moderate-to-severely active ulcerative colitis treated with biologics or small-molecule inhibitors. Official Journal of the American College of Gastroenterology| ACG, 115(6), 885–894.

Chen, F., Hu, Y., Fan, Y.-H., Lv, B. (2021). Clinical value of fecal calprotectin in predicting mucosal healing in patients with ulcerative colitis. Frontiers in Medicine, 8, 679264.

D’Amico, F., Bonovas, S., Danese, S., Peyrin‐Biroulet, L. (2020). faecal calprotectin and histologic remission in ulcerative colitis. Alimentary Pharmacology & Therapeutics, 51(7), 689–698.

Bromke, M. A., Neubauer, K., Kempiński, R., Krzystek-Korpacka, M. (2021). Faecal calprotectin in assessment of mucosal healing in adults with inflammatory bowel disease: a meta-analysis. Journal of Clinical Medicine, 10(10), 2203.

Stevens, T. W., Gecse, K., Turner, J. R., de Hertogh, G., Rubin, D. T., D’Haens, G. R. (2021). Diagnostic accuracy of fecal calprotectin concentration in evaluating therapeutic outcomes of patients with ulcerative colitis. Clinical Gastroenterology and Hepatology, 19(11), 2333–2342.

Petryszyn, P., Staniak, A., Wolosianska, A., Ekk-Cierniakowski, P. (2019). Faecal calprotectin as a diagnostic marker of inflammatory bowel disease in patients with gastrointestinal symptoms: meta-analysis. European Journal of Gastroenterology & Hepatology, 31(11), 1306–1312.

Khaki-Khatibi, F., Qujeq, D., Kashifard, M., Moein, S., Maniati, M., Vaghari-Tabari, M. (2020). Calprotectin in inflammatory bowel disease. Clinica Chimica Acta, 510, 556–565.

Chowdhury, M. F. K., Ghosh, C. K., Miah, M. S. A., Rassell, M., Hasan, M. A., Saha, C., et al. (2021). Faecal Calprotectin in Differentiating Inflammatory Bowel Disease (IBD) from Irritable Bowel Syndrome (IBS). Bangladesh Medical Journal, 50(1), 15–22.

Shimizu, H., Ebana, R., Kudo, T., Sato, T., Hara, T., Hosoi, K., et al. (2022). Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease. Journal of Gastroenterology, 57(5), 344–356.

Gür, E. S., Cindemir, Ö. (2020). The combined performance of fecal calprotectin with fecal occult blood, lymphocyte and neutrophil percentages in discriminating ulcerative colitis. Nobel Med J, 16, 13–21.